SynthesisBMC anesthesiology2026
Intranasal esketamine plus dexmedetomidine versus dexmedetomidine alone for emergence delirium in pediatric patients: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntranasal dexmedetomidine is commonly used preoperatively in pediatric anesthesia to reduce agitation and emergence delirium. Esketamine, with sedative and analgesic ef-fects and minimal respiratory depression at clinical doses, is also widely used in chil-dren. However, current evidence remains limited regarding the efficacy and safety of combining intranasal esketamine with dexmedetomidine versus dexmedetomidine alone in improving cooperation during anesthesia induction and reducing postoperative complications.
methodsThis meta-analysis adhered to PRISMA guidelines and was registered in PROSPERO (CRD420251084757). A systematic search of PubMed, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov, and Wanfang was conducted up to May 25, 2025. The primary outcome included the incidence of emergence delirium, emergence time, mask acceptance score (MAS), parental separation anxiety score (PSAS), and the incidence of adverse events, with pooled effect estimate reported as proportions and relative risk (RR) with 95% confidence intervals (CIs). Sensitivity analysis were performed to assess the robustness of the results and to identify sources of heterogeneity.
resultsSix studies involving a total of 515 pediatric patients were included. Compared with dexmedetomidine alone, intranasal esketamine combined with dexmedetomidine significantly reduces the incidence of emergence delirium (RR = 0.27, 95% CI: [0.17-0.44], P < 0.00001, I² = 0%). The incidence of bradycardia is also significantly lower in the combination group (RR = 0.24, 95% CI: [0.08-0.72], P = 0.01). No statistically significant differences are observed between the two groups in terms of emergence time or the incidence of nausea and vomiting. The combination group shows lower parental separation anxiety scores and better mask acceptance scores, indicating improved cooperation during anesthesia induction.
conclusionPreoperative intranasal administration of esketamine combined with dexmedetomidine significantly reduces the incidence of emergence delirium and bradycardia compared with dexmedetomidine alone.Improved cooperation during anesthesia induction further supports the potential of this combination as a safe and effective alternative to dexmedetomidine monotherapy in pediatric anesthesia.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.